Decreased olfactory function is very common in the older population, being present in >50% of individuals aged between 65 and 80 years and in 62-80% of those >80 years of age. Smell dysfunction significantly influences physical well-being, quality of life, nutritional status as well as everyday safety and is associated with increased mortality. Multiple factors contribute to age-related olfactory sensory loss, including nasal engorgement, cumulative damage of the olfactory epithelium from environmental insults, a reduction in mucosal metabolizing enzymes, sensory loss of receptor cells to odorants, and changes in neurotransmitter and neuromodulator systems. In addition, structural and functional abnormalities of the olfactory epithelium, olfactory bulb, central olfactory cortex, and basic olfactory circuitry, which are related to the neuronal expression of aberrant proteins in these areas, may result in olfactory sensory impairment in aging and neurodegenerative diseases. Impaired odour identification is associated with a decrease in cognitive abilities and memory decline. A reduction in the sense of smell is considered to potentially represent an early and important warning of neurodegenerative disorders, particularly of Parkinson's disease and Alzheimer's disease, and, in mild cognitive impairment, olfactory impairment may herald progression to dementia. Further investigations of the potential role of olfactory dysfunction in the early diagnosis and treatment of neurodegenerative diseases are warranted.

Keywords:
Olfaction, Olfactory system, Aging, Hyposmia, Neurodegeneration, Pathology
1.
Mobley AS, Rodriguez-Gil DJ, Imamura F, Greer CA: Aging in the olfactory system. Trends Neurosci 2014;37:77-84.
2.
Attems J, Walker L, Jellinger KA: Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol 2014;127:459-475.
3.
Benarroch EE: Olfactory system: functional organization and involvement in neurodegenerative disease. Neurology 2010;75:1104-1109.
4.
Doty RL: Olfaction in Parkinson's disease and related disorders. Neurobiol Dis 2012;46:527-552.
5.
Hawkes C: Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 2006;63:133-151.
6.
Magerova H, Vyhnalek M, Laczo J, Andel R, Rektorova I, Kadlecova A, Bojar M, Hort J: Odor identification in frontotemporal lobar degeneration subtypes. Am J Alzheimers Dis Other Demen 2014;29:762-768.
7.
Ruan Y, Zheng XY, Zhang HL, Zhu W, Zhu J: Olfactory dysfunctions in neurodegenerative disorders. J Neurosci Res 2012;90:1693-1700.
8.
Bramerson A, Johansson L, Ek L, Nordin S, Bende M: Prevalence of olfactory dysfunction: the skövde population-based study. Laryngoscope 2004;114:733-737.
9.
Huttenbrink KB, Hummel T, Berg D, Gasser T, Hahner A: Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int 2013;110:1-7.e1.
10.
Karpa MJ, Gopinath B, Rochtchina E, Jie Jin W, Cumming RG, Sue CM, Mitchell P: Prevalence and neurodegenerative or other associations with olfactory impairment in an older community. J Aging Health 2010;22:154-168.
11.
Schubert CR, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Pankow JS, Nondahl DM: Olfactory impairment in an adult population: the Beaver Dam Offspring Study. Chem Senses 2012;37:325-334.
12.
Doty RL, Kamath V: The influences of age on olfaction: a review. Front Psychol 2014;5:20.
13.
Lafreniere D, Mann N: Anosmia: loss of smell in the elderly. Otolaryngol Clin North Am 2009;42:123-131, x.
14.
Gallarda BW, Lledo PM: Adult neurogenesis in the olfactory system and neurodegenerative disease. Curr Mol Med 2012;12:1253-1260.
15.
Gopinath B, Sue CM, Kifley A, Mitchell P: The association between olfactory impairment and total mortality in older adults. J Gerontol A Biol Sci Med Sci 2012;67:204-209.
16.
Wilson RS, Yu L, Schneider JA, Arnold SE, Buchman AS, Bennett DA: Lewy bodies and olfactory dysfunction in old age. Chem Senses 2011;36:367-373.
17.
Kovacs T: The olfactory system in Alzheimer's disease: pathology, pathophysiology and pathway for therapy. Transl Neurosci 2013;4:34-45.
18.
Wilson RS, Arnold SE, Tang Y, Bennett DA: Odor identification and decline in different cognitive domains in old age. Neuroepidemiology 2006;26:61-67.
19.
Alves J, Petrosyan A, Magalhaes R: Olfactory dysfunction in dementia. World J Clin Cases 2014;2:661-667.
20.
Patel RM, Pinto JM: Olfaction: anatomy, physiology, and disease. Clin Anat 2014;27:54-60.
21.
Stephan AB, Shum EY, Hirsh S, Cygnar KD, Reisert J, Zhao H: ANO2 is the cilial calcium-activated chloride channel that may mediate olfactory amplification. Proc Natl Acad Sci USA 2009;106:11776-11781.
22.
Rawson NE: Olfactory loss in aging. Sci Aging Knowledge Environ 2006;2006:pe6.
23.
Whitman MC, Greer CA: Adult neurogenesis and the olfactory system. Prog Neurobiol 2009;89:162-175.
24.
Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, Martinez-Marcos A: Alpha-synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology. Brain Struct Funct 2014;219:1513-1526.
25.
Kay LM, Sherman SM: An argument for an olfactory thalamus. Trends Neurosci 2007;30:47-53.
26.
Kareken DA, Mosnik DM, Doty RL, Dzemidzic M, Hutchins GD: Functional anatomy of human odor sensation, discrimination, and identification in health and aging. Neuropsychology 2003;17:482-495.
27.
Haberly LB: Parallel-distributed processing in olfactory cortex: new insights from morphological and physiological analysis of neuronal circuitry. Chem Senses 2001;26:551-576.
28.
Attems J, Alpar A, Spence L, McParland S, Heikenwalder M, Uhlen M, Tanila H, Hokfelt TG, Harkany T: Clusters of secretagogin-expressing neurons in the aged human olfactory tract lack terminal differentiation. Proc Natl Acad Sci USA 2012;109:6259-6264.
29.
Rahayel S, Frasnelli J, Joubert S: The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis. Behav Brain Res 2012;231:60-74.
30.
Sinding C, Puschmann L, Hummel T: Is the age-related loss in olfactory sensitivity similar for light and heavy molecules? Chem Senses 2014;39:383-390.
31.
Doty RL, Petersen I, Mensah N, Christensen K: Genetic and environmental influences on odor identification ability in the very old. Psychol Aging 2011;26:864-871.
32.
Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han LY, Lee VM, Trojanowski JQ: Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 2010;67:462-469.
33.
Smith CG: Age incident of atrophy of olfactory nerves in man. J Comparat Neurol 1942;77:589-594.
34.
Buschhuter D, Smitka M, Puschmann S, Gerber JC, Witt M, Abolmaali ND, Hummel T: Correlation between olfactory bulb volume and olfactory function. Neuroimage 2008;42:498-502.
35.
Wang J, You H, Liu JF, Ni DF, Zhang ZX, Guan J: Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. AJNR Am J Neuroradiol 2011;32:677-681.
36.
Cai Y, Xue ZQ, Zhang XM, Li MB, Wang H, Luo XG, Cai H, Yan XX: An age-related axon terminal pathology around the first olfactory relay that involves amyloidogenic protein overexpression without plaque formation. Neuroscience 2012;215:160-173.
37.
Wu N, Rao X, Gao Y, Wang J, Xu F: Amyloid-beta deposition and olfactory dysfunction in an Alzheimer's disease model. J Alzheimers Dis 2013;37:699-712.
38.
Alvarado-Martinez R, Salgado-Puga K, Pena-Ortega F: Amyloid beta inhibits olfactory bulb activity and the ability to smell. PLoS One 2013;8:e75745.
39.
Bahar-Fuchs A, Chetelat G, Villemagne VL, Moss S, Pike K, Masters CL, Rowe C, Savage G: Olfactory deficits and amyloid-beta burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. J Alzheimers Dis 2010;22:1081-1087.
40.
Kishikawa M, Iseki M, Nishimura M, Sekine I, Fujii H: A histopathological study on senile changes in the human olfactory bulb. Acta Pathol Jpn 1990;40:255-260.
41.
Attems J, Jellinger KA: Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 2006;25:265-271.
42.
Segura B, Baggio HC, Solana E, Palacios EM, Vendrell P, Bargallo N, Junque C: Neuroanatomical correlates of olfactory loss in normal aged subjects. Behav Brain Res 2013;246:148-153.
43.
Adjei S, Houck AL, Ma K, Wesson DW: Age-dependent alterations in the number, volume, and localization of islands of Calleja within the olfactory tubercle. Neurobiol Aging 2013;34:2676-2682.
44.
Wilson RS, Arnold SE, Schneider JA, Tang Y, Bennett DA: The relationship between cerebral Alzheimer's disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry 2007;78:30-35.
45.
Bitter T, Gudziol H, Burmeister HP, Mentzel HJ, Guntinas-Lichius O, Gaser C: Anosmia leads to a loss of gray matter in cortical brain areas. Chem Senses 2010;35:407-415.
46.
Wang J, Eslinger PJ, Smith MB, Yang QX: Functional magnetic resonance imaging study of human olfaction and normal aging. J Gerontol A Biol Sci Med Sci 2005;60:510-514.
47.
Larsson M, Farde L, Hummel T, Witt M, Lindroth NE, Backman L: Age-related loss of olfactory sensitivity: association to dopamine transporter binding in putamen. Neuroscience 2009;161:422-426.
48.
Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI: Olfactory loss and nigrostriatal dopaminergic denervation in the elderly. Neurosci Lett 2010;484:163-167.
49.
Olofsson JK, Nordin S, Wiens S, Hedner M, Nilsson LG, Larsson M: Odor identification impairment in carriers of ApoE-varepsilon4 is independent of clinical dementia. Neurobiol Aging 2010;31:567-577.
50.
Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM: Olfactory impairment in older adults: five-year incidence and risk factors. Laryngoscope 2011;121:873-878.
51.
Schubert CR, Cruickshanks KJ, Nondahl DM, Klein BE, Klein R, Fischer ME: Association of exercise with lower long-term risk of olfactory impairment in older adults. JAMA Otolaryngol Head Neck Surg 2013;139:1061-1066.
52.
Masurkar AV, Devanand DP: Olfactory dysfunction in the elderly: basic circuitry and alterations with normal aging and Alzheimer's disease. Curr Geriatr Rep 2014;3:91-100.
53.
Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW: Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998;1:35-44.
54.
Chiu SL, Chen CM, Cline HT: Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 2008;58:708-719.
55.
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
56.
McNay EC, Ong CT, McCrimmon RJ, Cresswell J, Bogan JS, Sherwin RS: Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem 2010;93:546-553.
57.
Ott V, Benedict C, Schultes B, Born J, Hallschmid M: Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012;14:214-221.
58.
Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T: Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012;97:366-376.
59.
Stein MS, Scherer SC, Ladd KS, Harrison LC: A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J Alzheimers Dis 2011;26:477-484.
60.
Babizhayev MA, Deyev AI, Yegorov YE: Olfactory dysfunction and cognitive impairment in age-related neurodegeneration: prevalence related to patient selection, diagnostic criteria and therapeutic treatment of aged clients receiving clinical neurology and community-based care. Curr Clin Pharmacol 2011;6:236-259.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.